Answers are grounded in this paper and cite their sources.
Explores body composition's impact on infliximab response in Crohn's disease, suggesting sarcopenia as a risk factor.
Purpose: Although the advent of infliximab has improved clinical outcomes for patients with Crohn’s disease, a large proportion of patients still experience loss of response during treatment. The aim of our study was to explore the association between body composition parameters and the loss of response to infliximab in patients with Crohn’s disease(CD). Methods: 118 patients with CD admitted to the First Affiliated Hospital of Wenzhou Medical University and treated with infliximab from June 2015 to December 2021 were retrospectively enrolled. The body composition of patients was analyzed by computed tomography (CT). The primary outcome measure was the loss of response (LOR). Patients were divided into the Remission group and LOR group to analyze the association between body composition parameters and the loss of response to infliximab. Results The rate of sarcopenia in the LOR group was higher than the Remission group (83.7% vs. 60.0%, P=0.008). Multivariate analysis showed that females had a lower risk of sarcopenia than males (OR=0.30, 95%CI 0.11-0.81, P=0.017); BMI was significantly associated with sarcopenia (OR=0.68, 95%CI 0.56-0.83, P<0.001); L1 CD and L2 CD had a lower risk of sarcopenia than L3 CD (OR=0.29, 95%CI 0.10-0.83, P=0.021; OR=0.25, 95%CI 0.07-0.87, P=0.028). Conclusions Sarcopenia was identified as a risk factor for developing LOR in infliximab-treated patients.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2022) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: